Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation
暂无分享,去创建一个
G. Filippatos | F. Zannad | M. Packer | D. Farmakis | M. Brueckmann | J. Ferreira | A. Ofstad | T. Iwata | S. Anker | J. Butler | S. Pocock
[1] I. V. Van Gelder,et al. Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. , 2021, European heart journal.
[2] Akshay S. Desai,et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF , 2021, European journal of heart failure.
[3] A. Kjær,et al. Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial , 2021, The International Journal of Cardiovascular Imaging.
[4] P. Ponikowski,et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.
[5] H. Tse,et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis , 2021, Cardiovascular Diabetology.
[6] Ruicong Xue,et al. Usefulness of CHADS2, R2CHADS2, and CHA2DS2‐VASc scores for predicting incident atrial fibrillation in heart failure with preserved ejection fraction patients , 2021, ESC heart failure.
[7] L. Køber,et al. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial. , 2021, JAMA cardiology.
[8] B. Yeap,et al. Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes , 2020, The International Journal of Cardiovascular Imaging.
[9] D. Choi,et al. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction , 2020, Heart.
[10] L. Lund,et al. Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy , 2020, Circulation.
[11] B. Zinman,et al. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial , 2019, European journal of heart failure.
[12] G. Filippatos,et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry , 2018, European heart journal.
[13] L. Lund,et al. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. , 2017, JACC. Heart failure.
[14] A. Rigby,et al. Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. , 2017, Journal of the American College of Cardiology.
[15] G. Filippatos,et al. How to Use Beta-Blockers in Heart Failure With Reduced Ejection Fraction and Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.
[16] I. V. Van Gelder,et al. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume. , 2017, JACC. Heart failure.
[17] V. Roger,et al. Temporal Relationship and Prognostic Significance of Atrial Fibrillation in Heart Failure Patients With Preserved Ejection Fraction: A Community-Based Study , 2013, Circulation.